【摘要】 目的:探讨希罗达单药治疗晚期恶性肿瘤的近期疗效及不良反应。方法:43例晚期恶性肿瘤患者均给予希罗达口服,每日2次,餐后服用,2 500mg/m2.d,连续服用14d后停药7d,治疗周期为21d,至少治疗2个周期。结果:43例均可评价,完全缓解(CR)1例,部分缓解(PR)11例,病情稳定(SD)20例,疾病进展(PD)11例,总有效率27.9%,临床获益率74.4%。不良反应:手足综合征(HFS)22例,色素沉着21例,恶心10例,呕吐8例,厌食12例,腹泻10例,白细胞下降12例,血小板下降4例,大多数为Ⅰ~Ⅱ度,2例Ⅲ度HFS,1例Ⅲ度色素沉着。结论:希罗达治疗晚期恶性肿瘤疗效肯定,用药方便,耐受性好,不良反应轻。更多还原

【Abstract】 Objective:To evaluate the efficacy and safety of single-agent Xeloda in patients with advanced cancer.Methods:43 patients were treated with Xeloda,2500mg/m2/d,twice daily,on days 1~14 every 21 days.At least 2 cycles were administered.Results:The overall response rate was 27.9%,the benefit rates were 74.4%,with 1 CR,11 PR,20 SD and 11 PD.In terms of adverse reaction,foot and hand syndrome could be seen in 22 patients,skin pigmentation in 21 patients.Nausea,vomiting,anorexia and diarrhea were observed in 10,8,12 and 10 cases;12 and 4 patients had mild granulocytopenia and thrombocytopennia.Conclusion: xeloda is and efficacious and better-tolerated alternative treatment for the patients with advanced cancer.更多还原